Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions

In English

Författare

  • Peter Carmeliet
  • Lieve Moons
  • Aernout Luttun
  • Valeria Vincenti
  • Veerle Compernolle
  • Maria De Mol
  • Yan Wu
  • Françoise Bono
  • Laetitia Devy
  • Heike Beck
  • Dimitri Scholz
  • Till Acker
  • Tina DiPalma
  • Mieke Dewerchin
  • Agnes Noel
  • Ingeborg Stalmans
  • Adriano Barra
  • Sylvia Blacher
  • Thierry Vandendriessche
  • Annica Pontén
  • Ulf Eriksson
  • Karl H. Plate
  • Jean-Michel Foidart
  • Wolfgang Schaper
  • D. Stephen Charnock-Jones
  • Daniel J. Hicklin
  • Jean-Marc Herbert
  • Désiré Collen
  • M. Graziella Persico
Visa allt

Summary, in English

Vascular endothelial growth factor (VEGF) stimulates angiogenesis by activating VEGF receptor-2 (VEGFR-2). The role of its homolog, placental growth factor (PlGF), remains unknown. Both VEGF and PlGF bind to VEGF receptor-1 (VEGFR-1), but it is unknown whether VEGFR-1, which exists as a soluble or a membrane-bound type, is an inert decoy or a signaling receptor for PlGF during angiogenesis. Here, we report that embryonic angiogenesis in mice was not affected by deficiency of PlGF (Pgf-/-). VEGF-B, another ligand of VEGFR-1, did not rescue development in Pgf-/- mice. However, loss of PlGF impaired angiogenesis, plasma extravasation and collateral growth during ischemia, inflammation, wound healing and cancer. Transplantation of wild-type bone marrow rescued the impaired angiogenesis and collateral growth in Pgf-/- mice, indicating that PlGF might have contributed to vessel growth in the adult by mobilizing bone-marrow-derived cells. The synergism between PlGF and VEGF was specific, as PlGF deficiency impaired the response to VEGF, but not to bFGF or histamine. VEGFR-1 was activated by PlGF, given that anti-VEGFR-1 antibodies and a Src-kinase inhibitor blocked the endothelial response to PlGF or VEGF/PlGF. By upregulating PlGF and the signaling subtype of VEGFR-1, endothelial cells amplify their responsiveness to VEGF during the 'angiogenic switch' in many pathological disorders.

Publiceringsår

2001

Språk

Engelska

Sidor

575-583

Publikation/Tidskrift/Serie

Nature Medicine

Volym

7

Issue

5

Dokumenttyp

Artikel i tidskrift

Förlag

Nature Publishing Group

Ämne

  • Cell and Molecular Biology

Status

Published

ISBN/ISSN/Övrigt

  • ISSN: 1546-170X